|1.||Pommier, Yves: 6 articles (09/2015 - 01/2003)|
|2.||Cushman, Mark: 3 articles (02/2014 - 12/2003)|
|3.||Soda, Hiroshi: 3 articles (11/2006 - 08/2003)|
|4.||Nakamura, Yoichi: 3 articles (11/2006 - 08/2003)|
|5.||Shiozawa, Ken: 3 articles (11/2006 - 08/2003)|
|6.||Oka, Mikio: 3 articles (11/2006 - 08/2003)|
|7.||Kohno, Shigeru: 3 articles (11/2006 - 08/2003)|
|8.||Kitazaki, Takeshi: 3 articles (11/2006 - 08/2003)|
|9.||Choy, Hak: 3 articles (06/2004 - 01/2002)|
|10.||Cummings, Jeffrey: 3 articles (01/2004 - 02/2002)|
08/01/2005 - "These findings suggest that reducing the levels of these critical antiapoptotic factors may increase the efficacy of topoisomerase I inhibitors in the clinical setting if given in a sequence that does not prevent or inhibit tumor cell progression through the S phase."
03/01/2001 - "Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. "
02/27/2014 - "Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells."
12/01/2014 - "ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses."
01/01/2013 - "Taken together, our findings demonstrate that prolonged exposure to topoisomerase I inhibitors is accompanied by upregulation of different signal transduction pathways which can alter tumor sensitivity to molecular targeted agents. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
12/01/1999 - "Over the past 10 years, a number of topoisomerase I inhibitors have entered into clinical trials and several of these have been evaluated in phase II and III studies to determine their activity in patients with advanced colorectal cancer. "
03/01/2003 - "Topoisomerase I inhibitors have been shown to have clinical activity against human colorectal cancer. "
10/15/2000 - "Topoisomerase I inhibitors have demonstrated clinical activity in patients with metastatic colorectal carcinoma. "
12/01/1999 - "In summary, extensive evaluation of topoisomerase I inhibitors has identified a significant degree of variability in clinical activity in patients with advanced colorectal cancer. "
12/01/1999 - "The role of other topoisomerase I inhibitors in colorectal cancer has been more difficult to characterize. "
|3.||Colonic Neoplasms (Colon Cancer)
02/15/2002 - "Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation."
12/13/1996 - "Topoisomerase-I inhibitors in the management of colon cancer."
06/01/2014 - "MOG-19 and MOG-13 were characterized in vitro using kinase, viability, and apoptosis assays in different human colon cancer (HT-29, HCT-116, Caco-2, and SW480) and normal colon cell lines (CCD-18Co, FHC, and HCoEpiC) alone or in combination with topoisomerase I inhibitors. "
11/16/2011 - "By contrast, MC70 was found to inhibit cell growth in colon cancer cells without affecting doxorubicin efficacy and in combination with topoisomerase I inhibitors it could be a promising therapeutic approach. "
12/01/2003 - "We have shown that human colon cancer cells are efficient in drug conjugation catalyzed by UDP-glucuronosyltransferases (UGTs) and now report on the role of glucuronidation in de novo resistance to two topoisomerase I inhibitors. "
|4.||Hepatocellular Carcinoma (Hepatoma)
03/01/2014 - "Taken together, our data show for the first time that HIF-1α is strongly correlated with resistance to topoisomerase I inhibitors in hepatocellular carcinoma. "
03/01/2014 - "Here, we present in vitro and in vivo evidence that the extremely high level of hypoxia-inducible factor-1α (HIF-1α) in hepatocellular carcinoma is intimately correlated with resistance to topoisomerase I inhibitors. "
03/01/2014 - "These results suggest that HIF-1α is a promising target and provide a rationale for clinical trials investigating the efficacy of the combination of topoisomerase I inhibitors and tirapazamine in hepatocellular cancers."
03/01/2014 - "In this study, we investigated that in combination with tirapazamine, topoisomerase I inhibitors exhibited synergistic cytotoxicity and induced significant apoptosis in several hepatocellular carcinoma cell lines. "
03/01/2014 - "Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α."
|5.||Breast Neoplasms (Breast Cancer)
01/01/2000 - "Transport of topoisomerase I inhibitors by the breast cancer resistance protein. "
11/01/2006 - "Breast cancer resistance protein (BCRP) confers resistance against topoisomerase I inhibitors in cancer cells. "
01/01/1995 - "Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy."
02/15/2005 - "Here, to explore the mechanism with topoisomerase I inhibitors, we focused on the efflux pump of the breast cancer resistance protein (BCRP/ABCG2), and then examined whether gefitinib restored drug sensitivity in multidrug-resistant cancer cells overexpressing BCRP. "
01/01/1995 - "The topoisomerase 1 inhibitors topotecan and camptothecin 11 (CPT-11) have been less extensively evaluated in breast cancer therapy. "
|5.||tirapazamine (SR 4233)
|8.||Type I DNA Topoisomerases (Topoisomerase I)
|10.||Etoposide (VP 16)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|5.||Combined Modality Therapy